ENDECE

ENDECE developed NDC-1308 a novel therapeutic for COVID-19, reducing inflammation as well as the nu

ENDECE is a biopharmaceutical company developing a healthier future by addressing the needs of people suffering from debilitating and life threatening diseases. ENDECE scientists have created a library of proprietary compounds with the ability to modify specific gene expression, and restore function. Fueled by highly experienced scientific minds and industry leaders, the ENDECE therapeutic drug platform is poised to achieve regulatory and clinical milestones, improve lives, and develop a healthier future for those suffering.

01/21/2021

https://endece.com/ndc-1308-a-novel-therapeutic-for-acute-respiratory-distress-syndrome-ards-including-covid-19-patients/

As SARS-Cov-2 / COVID-19 continues to dominate our lives, the world is looking for a way to get back to “Normal”. Unfortunately, “Normal”, is a long ways off and may have to be redefined in general. ENDECE is excited about the promise of NDC-1308 for the treatment of Acute Respiratory Distress Syndrome (ARDS) and specifically as a much needed treatment of ARDS in COVID-19 patients.

NDC-1308 is a novel therapeutic for Acute Respiratory Distress Syndrome (ARDS) including SARS-CoV-2 and COVID-19 patients

Address

Portland, OR

Telephone

+15035362639

Website

https://endece.com/

Alerts

Be the first to know and let us send you an email when ENDECE posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to ENDECE:

Shortcuts

Want your practice to be the top-listed Clinic in Portland?

NDC-1308 (MC1)

ENDECE is preparing to take NDC-1308 (MC1) into clinical studies as a therapeutic for COVID-19. By addressing early signs of lung inflammation in patients, NDC-1308 (MC1) can reduce the amount of time people spend in hospitals and prevent the use of ventilators.